» Articles » PMID: 20733102

Ten-year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a Randomized Controlled Clinical Trial of 3 Therapeutic Strategies for Multivessel Coronary Artery Disease

Overview
Journal Circulation
Date 2010 Aug 25
PMID 20733102
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

Background: This study compared the 10-year follow-up of percutaneous coronary intervention (PCI), coronary artery surgery (CABG), and medical treatment (MT) in patients with multivessel coronary artery disease, stable angina, and preserved ventricular function.

Methods And Results: The primary end points were overall mortality, Q-wave myocardial infarction, or refractory angina that required revascularization. All data were analyzed according to the intention-to-treat principle. At a single institution, 611 patients were randomly assigned to CABG (n=203), PCI (n=205), or MT (n=203). The 10-year survival rates were 74.9% with CABG, 75.1% with PCI, and 69% with MT (P=0.089). The 10-year rates of myocardial infarction were 10.3% with CABG, 13.3% with PCI, and 20.7% with MT (P<0.010). The 10-year rates of additional revascularizations were 7.4% with CABG, 41.9% with PCI, and 39.4% with MT (P<0.001). Relative to the composite end point, Cox regression analysis showed a higher incidence of primary events in MT than in CABG (hazard ratio 2.35, 95% confidence interval 1.78 to 3.11) and in PCI than in CABG (hazard ratio 1.85, 95% confidence interval 1.39 to 2.47). Furthermore, 10-year rates of freedom from angina were 64% with CABG, 59% with PCI, and 43% with MT (P<0.001).

Conclusions: Compared with CABG, MT was associated with a significantly higher incidence of subsequent myocardial infarction, a higher rate of additional revascularization, a higher incidence of cardiac death, and consequently a 2.29-fold increased risk of combined events. PCI was associated with an increased need for further revascularization, a higher incidence of myocardial infarction, and a 1.46-fold increased risk of combined events compared with CABG. Additionally, CABG was better than MT at eliminating anginal symptoms. Clinical Trial Registration Information- URL: http://www.controlled-trials.com.

Registration Number: ISRCTN66068876.

Citing Articles

Outcomes with revascularisation versus conservative management of participants with 3-vessel coronary artery disease in the ISCHEMIA trial.

Bangalore S, Rhodes G, Maron D, Anthopolos R, OBrien S, Jones P EuroIntervention. 2024; 20(20):e1276-e1287.

PMID: 39432255 PMC: 11472139. DOI: 10.4244/EIJ-D-24-00240.


Progress in the Application of the Residual SYNTAX Score and Its Derived Scores.

Lin X, Mei Z, Ji W, Wang Y, Xu C Rev Cardiovasc Med. 2024; 25(3):80.

PMID: 39076942 PMC: 11263829. DOI: 10.31083/j.rcm2503080.


Hemoadsorption in Heart Failure Requiring Mechanical Circulatory Support-A Systematic Review and Meta-Analysis.

Freiburger S, Caldonazo T, Tasoudis P, Farber G, Schulze P, Franz M Rev Cardiovasc Med. 2024; 24(5):137.

PMID: 39076733 PMC: 11273042. DOI: 10.31083/j.rcm2405137.


Association between the C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index and Adverse Clinical Outcomes in CAD Patients after PCI: Findings of a Real-World Study.

Pan Y, Wu T, Deng C, Jiang Z, Yang Y, Hou X Rev Cardiovasc Med. 2024; 25(4):111.

PMID: 39076545 PMC: 11264017. DOI: 10.31083/j.rcm2504111.


Long-Term Outcomes of Sex Differences in Three-Vessel Coronary Disease with Different Treatment Strategies: A Large Cohort Study.

Li J, Jiang L, Xu L, Tian J, Feng X, Wang D Glob Heart. 2024; 19(1):57.

PMID: 38973986 PMC: 11225599. DOI: 10.5334/gh.1333.